Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings, Inc. (NYSE American: INFU) regularly issues news and press releases that are of interest to investors, analysts and others following the health care services and durable medical equipment space. The company describes itself as a national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers, with operations organized into Patient Services and Device Solutions platforms.
News items about InfuSystem often include quarterly and annual financial results, where the company discusses net revenues, segment performance for Patient Services and Device Solutions, gross margin trends, cash flow, and Adjusted EBITDA. These releases typically highlight how oncology, pain management and wound therapy within Patient Services, as well as rentals, pump and consumable sales, and biomedical services within Device Solutions, have contributed to overall results.
Another common category of news involves guidance and outlook. InfuSystem has used press releases to provide or reaffirm guidance ranges for net revenue growth and Adjusted EBITDA margin for upcoming fiscal years, and to explain how factors such as revenue mix, information technology projects, and capital expenditures may affect margins and cash flow.
The company also issues announcements about leadership changes and corporate governance, such as the CEO transition disclosed in April 2025, and about participation in investor conferences hosted by firms like ROTH and Craig-Hallum. These items often note that management will host one-on-one or small group meetings with investors.
In addition, InfuSystem uses news releases to communicate regulatory and policy developments that affect its business. For example, an 8-K dated December 10, 2025 references a press release announcing that the Centers for Medicare and Medicaid Services added two electronic infusion pumps used in the company’s Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.
Visitors to the INFU news page can review this stream of financial updates, guidance, leadership announcements, conference participation notices and regulatory disclosures to understand how the company describes its performance and strategic priorities over time.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced a new stock repurchase program to buy back up to $20 million of its common stock through June 30, 2024. This program replaces the prior authorization that expired on December 31, 2020, and is intended to enhance shareholder value. CEO Richard DiIorio expressed confidence in the company's operations and future growth prospects, emphasizing the program's role in strategic capital allocation.
InfuSystem announced a strategic agreement with Bio Compression Systems to integrate Lymphedema Therapy into its Integrated Therapy Service platform. This addition marks the fourth therapy service for InfuSystem, complementing its existing offerings in Oncology, Pain Management, and Wound Care. The company expects significant revenue contributions from this new therapy beginning in 2022. InfuSystem's recent CHAP accreditation will facilitate new patient onboarding within 60 days, addressing approximately 20% of the Lymphedema market.
InfuSystem Holdings, a prominent healthcare service provider, will participate in Craig-Hallum’s 18th Annual Institutional Investor Conference on June 2, 2021. CEO Rich DiIorio and CFO Barry Steele will engage in virtual one-on-one meetings throughout the day. Investors can contact Craig-Hallum or Lytham Partners for meeting arrangements. InfuSystem operates under two platforms: Integrated Therapy Services, focusing on complex durable medical equipment for outpatient care, and Durable Medical Equipment Services, which enhances service offerings to clients.
InfuSystem Holdings reported a strong performance for Q1 2021, with net revenues of $24.5 million, a 14% increase year-over-year. The company achieved a net income of $0.7 million, up $1.1 million from the prior year, alongside an Adjusted EBITDA of $6.2 million, marking a 51% growth. The Adjusted EBITDA margin was 25.2%. InfuSystem reaffirmed its 2021 full-year guidance, anticipating revenues between $107 million and $110 million, with a projected Adjusted EBITDA margin of 27%.
InfuSystem Holdings, Inc. (NYSE American: INFU) will release its first quarter 2021 financial results on May 6, 2021, before the market opens. The Company provides outpatient care for durable medical equipment manufacturers and health care providers. A conference call for investors is scheduled for the same day at 9:00 a.m. Eastern Time to discuss the results. Investors can participate via phone or a live webcast, with a replay available for 90 days after the call.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the acquisition of assets from OB Healthcare Corporation, a Texas-based biomedical services firm. This strategic move enhances InfuSystem's Durable Medical Equipment Services (DME) platform, following a recent acquisition of FilAMed. The combination of OB Healthcare's on-site service capabilities and FilAMed's remote repair expertise aims to expand InfuSystem's market opportunities in acute care. CEO Richard DiIorio emphasized the synergy between both companies, which is expected to improve service offerings for their healthcare clients.
InfuSystem Holdings (NYSE American: INFU) will present at Sidoti’s Spring 2021 Virtual Conference on March 25, 2021, at 9:15 a.m. ET. CEO Rich DiIorio and CFO Barry Steele will discuss the company's role as a leading healthcare service provider facilitating outpatient care for durable medical equipment. Their services include Integrated Therapy Services and Durable Medical Equipment Services. Management will also hold one-on-one meetings with investors on March 24-25. A recorded webcast will be available afterward on InfuSystem’s website.
InfuSystem Holdings reported a remarkable financial performance for the full year 2020, reflecting a 20% increase in net revenues, reaching $97.4 million, and a 15.9 million surge in net income, totaling $17.3 million. Adjusted EBITDA climbed 44% to $26.2 million. For 2021, the company reaffirms its guidance with projected net revenues of $107 million - $110 million and adjusted EBITDA of $29 million - $30 million. Notably, the fourth quarter saw a 14% revenue increase, driven by significant growth in oncology and DME services.
InfuSystem Holdings, Inc. (NYSE American: INFU) will release its fourth quarter and full year 2020 financial results on March 17, 2021, before market opening. The company provides outpatient care services for durable medical equipment. Following the results announcement, a conference call will be held at 9:00 a.m. Eastern Time to discuss the financials. Investors can participate by calling (833) 366-1127 or through a live webcast on the company’s website. A replay will be available for 90 days.
InfuSystem Holdings announces the promotion of Carrie Lachance to President, adding to her current role as Chief Operating Officer. CEO Richard DiIorio praised her leadership in patient and customer care. This leadership change aims to strengthen the company’s growth strategy and enhance its two operational platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME). Lachance, with over 20 years of healthcare experience, focuses on scaling new therapies and products.